comparemela.com

Latest Breaking News On - Rocket pharmaceuticals - Page 4 : comparemela.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Issues Quarterly Earnings Results, Beats Estimates By $0.01 EPS

Rocket Pharmaceuticals (NASDAQ:RCKT) Issues Quarterly Earnings Results, Beats Estimates By $0.01 EPS
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Kinnari-patel
Davidp-southwell
Rocket-pharmaceuticals-inc
News-ratings-for-rocket-pharmaceuticals-daily
Jpmorgan-chase-co
Goldman-sachs-group
Securities-exchange-commission
Rocket-pharmaceuticals
Earnings-history-for-rocket-pharmaceuticals
Cantor-fitzgerald
Rocket-pharmaceuticals-stock-performance
Rocket-pharmaceuticals-company-profile

Equities Research Analysts' Updated EPS Estimates for May 7th (ACLX, ADEA, ADUS, AHT, ALTO, AMG, AMR, AVNS, AXON, AXSM)

Equities Research Analysts' Updated EPS Estimates for May 7th (ACLX, ADEA, ADUS, AHT, ALTO, AMG, AMR, AVNS, AXON, AXSM)
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Canada
Piper-sandler
Roth-mkm
William-blair
Telsey-advisory-group
Biocryst-pharmaceuticals
Barclays-plc
Maxim-group
Fidelity-national-information-services
Alliance-global-partners
Equities-research-analyst
Royal-bank

Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress

Advanced RP-L102 for Fanconi Anemia towards regulatory reviews; EMA accepted MAA for review and BLA submission anticipated in the first half of 2024 Continued preparations to launch LV portfolio.

California
United-states
Stanford-university
American
America
Los-angeles
Agnieszka-czechowicz
Donaldb-kohn
Gaurav-shah
Company-cranbury
Dodge
Stanford-university-school-of-medicine

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Average Rating of "Moderate Buy" by Brokerages

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Average Rating of "Moderate Buy" by Brokerages
themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.

Wellington
New-zealand-general
New-zealand
Gotham-makker
Davidp-southwell
Wellington-management-group
Vanguard-group-inc
Rocket-pharmaceuticals-price-performance
Cantor-fitzgerald
Institutional-trading-of-rocket-pharmaceuticals
Goldman-sachs-group
Westfield-capital-management-co

Rocket Pharmaceuticals Upgraded to Buy: Here's Why

Investors might want to bet on Rocket Pharmaceuticals RCKT, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates…

Rocket-pharmaceuticals
Zacks-rank
Zacks-consensus
News
Ggregator
Reaking-news
Uration
Media

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.